Dxcover Presents Groundbreaking Real-World Evidence Linking Early Brain Tumor Detection to Reduced Mortality and Healthcare Costs

Dxcover Limited, a clinical-stage diagnostics company based in Glasgow, Scotland, and Nashville, Tennessee, has announced the presentation of groundbreaking real-world evidence demonstrating a strong correlation between increased tumor size and higher mortality rates in patients with brain cancer. This new data, presented by Dr. Ewan Gray, PhD, Head of Health Economic & Outcomes Data at Dxcover, and Dr. James Cameron, PhD, Clinical Program Manager at Dxcover, at two major international conferences—Ca-PRI in Manchester, UK, and AACR in Chicago, USA—highlights the critical importance of early diagnosis in improving survival rates and reducing healthcare costs. The study, which analyzed data from 1,196 patients in an existing registry, found that identifying brain tumors at a smaller size can significantly reduce mortality. Specifically, the research suggests that diagnosing brain tumors just one month earlier could lower the annual risk of mortality by 18-28%. This early detection not only increases the likelihood of successful treatment but also reduces the time patients spend in hospitals, thereby lowering healthcare expenditures. Professor Paul Brennan, an author on the study and Professor of Clinical and Experimental Neurosurgery at the University of Edinburgh, emphasized the significance of these findings: “Prioritizing people with symptoms of a possible brain tumor for urgent brain imaging does matter. These data make it clear that earlier diagnosis can lead to better outcomes and reduced hospital stays, encouraging healthcare professionals and organizations to implement strategies for early detection.” Dxcover’s innovative PANAROMIC™ platform, which stands out in the field of multiomic spectral analysis (MOSA-Dx™), is designed to detect the presence of various cancers, including brain cancer, at their earliest stages. Unlike conventional genetic tests that focus solely on tumor DNA, Dxcover's technology uses infrared spectroscopy combined with advanced AI algorithms to analyze a patient’s blood. This method captures a comprehensive spectrum of molecular signals, providing a more detailed and accurate picture of the patient's condition. The platform’s unparalleled sensitivity is achieved through the vibration of molecules using infrared light, producing a distinct spectral signature that characterizes the entire sample. This holistic approach enables the detection of cancers that traditional methods may miss, offering a non-invasive, rapid, and cost-effective solution. Dxcover’s patented Drop. Dry. Detect™ method requires only small amounts of blood, making it highly practical for high-throughput testing. Cameron Miller, Director of External Affairs and Strategy at The Brain Tumor Charity, commented on the potential impact of the findings: “There are 130 different types of brain tumors, each requiring specific treatment depending on their location and grade. Early diagnosis is crucial for optimizing patient care. This study’s real-world evidence is significant because it shows that faster diagnosis can both reduce NHS spending and potentially save lives.” Professor Matthew J. Baker, Co-Founder, CEO, and President of Dxcover, stated: “The data presented today underscores the potential of our PANAROMIC™ liquid biopsy platform to transform brain cancer outcomes. Early detection can enable the development of novel treatments and improve survival rates, making our platform a game-changer in cancer diagnostics.” Dxcover’s mission is to deploy the PANAROMIC™ platform for the early detection of high-mortality and hard-to-diagnose cancers, focusing on high-risk populations and facilitating value-based cancer care. The company aims to be the world leader in liquid biopsy and AI in cancer diagnostics, striving for better survival and quality of life for patients. With a robust foundation of data from over 9,000 patients and 250,000 spectra, Dxcover’s AI algorithms offer flexibility in adjusting sensitivity or specificity as needed. Industry experts and advocates agree that Dxcover’s findings could have a profound impact on how brain cancer is diagnosed and treated. The potential to reduce mortality rates and healthcare costs, while improving patient outcomes, makes this a compelling case for investment in advanced diagnostic technologies. Dxcover’s continued development of its PANAROMIC™ platform holds promise not only for brain cancer but also for a broader range of cancers, positioning the company at the forefront of early cancer detection innovation. For more information about Dxcover and its technology, visit https://www.dxcover.com/science.